CHE — Chemed Corporation Stock Price, Chart & AI Report

Negative Feb 26, 2026 • 22:18 UTC GlobeNewswire Inc. • Johnson Fistel, Pllp

Chemed Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Johnson Fistel, PLLP is investigating potential securities law violations by Chemed Corporation following the company's February 26, 2026 earnings report that missed consensus estimates by $0.61 per share and $19.8 million in revenue, resulting in a stock price decline. The law firm is seeking investors who suffered losses to join the investigation.

CHE securities fraud earnings miss investor losses class action investigation federal securities laws financial results

Sentiment note

Chemed reported fourth quarter 2025 results that significantly missed analyst expectations (EPS miss of $0.61 and revenue miss of $19.8 million), leading to a stock price decline and triggering a securities investigation into potential compliance violations with federal securities laws.

Neutral Feb 16, 2026 • 17:15 UTC The Motley Fool • Jonathan Ponciano

Chemed Stock Down 15% in a Year as One Fund Builds a $5.56 Million Stake

Barington Companies Management established a new position in Chemed Corporation by acquiring 13,000 shares valued at $5.56 million, representing 3.65% of its reportable assets. Despite Chemed's stock declining 15.18% over the past year, the investment signals conviction in the company's strong balance sheet, cash generation, and defensive business model spanning hospice care (VITAS) and plumbing services (Roto-Rooter), despite recent margin pressures.

CHE Chemed Corporation Barington Companies Management hospice care Roto-Rooter stock decline institutional investment balance sheet strength

Sentiment note

While the stock has declined 15% year-over-year and faced recent margin pressures and EPS declines, the company maintains strong fundamentals including $129.8 million in cash, no debt, consistent revenue growth (3.1% YoY), and positive demographic tailwinds in hospice care. The institutional investment by Barington suggests confidence in long-term value despite short-term sentiment weakness.

Positive Feb 13, 2026 • 18:20 UTC Benzinga • Globe Newswire

Chemed Corporation Board of Directors Authorizes an Additional $300 Million for Stock Repurchase and Declares Quarterly Dividend of 60 Cents

Chemed Corporation announced a $300 million authorization for stock repurchases and declared a quarterly dividend of $0.60 per share, payable on March 13, 2026. This marks the 219th consecutive quarterly dividend in the company's 54 years as a public company. The repurchases will be funded through operational cash flow and its revolving credit facility.

CHE stock repurchase dividend shareholder returns capital allocation hospice care plumbing services

Sentiment note

The company is demonstrating strong financial health and confidence in its business by authorizing a substantial $300 million share repurchase program and maintaining consistent dividend payments (219 consecutive quarters). These actions indicate robust cash generation and shareholder-friendly capital allocation, which are typically viewed positively by investors.

Positive Nov 7, 2025 • 16:28 UTC Benzinga • Globe Newswire

Chemed Corporation Declares Quarterly Dividend of 60 Cents

Chemed Corporation announced a quarterly cash dividend of 60 cents per share, payable on December 5, 2025, to shareholders of record as of November 17, 2025. This marks the 218th consecutive quarterly dividend in the company's 54-year history.

CHE dividend quarterly dividend hospice care plumbing services

Sentiment note

Consistent dividend payment demonstrates financial stability and commitment to shareholders, with this being their 218th consecutive quarterly dividend

Neutral Nov 4, 2025 • 17:00 UTC GlobeNewswire Inc. • Michael D. Witzeman

Chemed Corporation to Present at the UBS 2025 Global Healthcare Conference

Chemed Corporation will present at the UBS 2025 Global Healthcare Conference, discussing its performance across its two subsidiaries: VITAS Healthcare and Roto-Rooter.

CHE healthcare conference earnings hospice care plumbing services

Sentiment note

The article presents standard corporate communication about an upcoming conference presentation without indicating significant positive or negative performance indicators

Negative Nov 2, 2025 • 16:25 UTC The Motley Fool • Cory Renauer

Schwartz Offloads 28,000 Chemed (CHE) Shares Valued at $13 Million

Schwartz Investment Counsel sold 28,771 shares of Chemed Corporation, reducing its stake to 111,033 shares, representing 1.67% of its reportable assets. The sale was driven by disappointing quarterly results and declining performance in both hospice care and plumbing segments.

CHE MA NVDA Chemed stock sale hospice care plumbing services investment

Sentiment note

Stock is down 33.7% from its peak, reported disappointing Q3 results with declining EBITDA in both hospice care and Roto-Rooter segments, and underperformed the S&P 500 by 45.55 percentage points over the past year

Unknown May 25, 2024 • 05:51 UTC Seeking Alpha • Justin Law

Dividend Champion, Contender, And Challenger Highlights: Week Of May 26

Stay up-to-date on dividend activity, changes, ex-dividend dates, and pay dates for Dividend Champions, Contenders, and Challengers in our weekly summary.

EQH FLO HLNE LII

Unknown May 24, 2024 • 15:31 UTC Zacks Investment Research • Zacks Equity Research

Chemed (CHE) Down 3.1% Since Last Earnings Report: Can It Rebound?

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CHE

Unknown May 16, 2024 • 10:20 UTC Zacks Investment Research • Zacks Equity Research

Should iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) Be on Your Investing Radar?

Style Box ETF report for SMMV

SMMV MUSA CHE IWM

Unknown May 1, 2024 • 15:40 UTC Zacks Investment Research • Zacks Equity Research

EHC or CHE: Which Is the Better Value Stock Right Now?

EHC vs. CHE: Which Stock Is the Better Value Option?

EHC CHE

Unknown Apr 25, 2024 • 12:27 UTC Zacks Investment Research • Zacks Equity Research

Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View

Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.

PODD CHE EXAS INSP

Unknown Apr 24, 2024 • 22:10 UTC Zacks Investment Research • Zacks Equity Research

Chemed (CHE) Q1 Earnings Miss Estimates

Chemed (CHE) delivered earnings and revenue surprises of -4.94% and 0.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

CHE ATIP